Concepedia

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel,

Annals of Oncology · 2022 · 81 citations · 10 references

DOI

Concepts

References

10

IC3D Classification of Corneal Dystrophies—Edition 2

Jayne S. Weiss, Hans Ulrik Møller, Anthony J. Aldave et al. · Cornea · 2015 · 513 citations · Full text

, , +13

Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates

Hans K. Erickson, Wayne C. Widdison, Michele Mayo et al. · Bioconjugate Chemistry · 2009 · 240 citations

, , +17

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Nizar M. Tannir, Andres Forero‐Torres, Radhakrishnan Ramchandren et al. · Investigational New Drugs · 2014 · 129 citations

, , +14

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

Efrat Dotan, Steven J. Cohen, Alexander Starodub et al. · Journal of Clinical Oncology · 2017 · 118 citations · Full text

, , +17

Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors

Stéphanie Decary, Pierre‐François Berne, Céline Nicolazzi et al. · Clinical Cancer Research · 2020 · 80 citations · Full text

, , +17